On this basis, several clinical trials have been recently opened to test the clinical benefit of GR antagonists (e.g. mifepristone/RU486, CORT125134) as single agents or in combination with standard of care therapy for several late stage cancers (www.clinicaltrials.gov). This evidence concerns the gene NR3C1 and cancer.